Efficacy, safety and cost-effectiveness of chemo-immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated systematic review and cost-effectiveness analysis
In summary, while TisGP shows a clinically favorable trend in efficacy and safety, TorGP demonstrates superior cost-effectiveness with an incremental cost-effectiveness ratio well below the willingness-to-pay threshold. This finding suggests that clinicians should comprehensively evaluate individual patient characteristics when selecting treatment regimens.
Authors
- Qiran Wei
- Yuting Xu (ORCID: https://orcid.org/0000-0001-7640-4018)
- Yinjiao Fei (ORCID: https://orcid.org/0000-0003-3354-4082)
- Yuandong Cao (ORCID: https://orcid.org/0000-0002-9905-7941)
- Yuxin Hu (ORCID: https://orcid.org/0000-0001-8045-9978)
- Mengxing Wu
- Weilin Xu (ORCID: https://orcid.org/0000-0001-5476-5541)
- Pu Juan (ORCID: https://orcid.org/0000-0001-9975-124X)
- Shu Zhou (ORCID: https://orcid.org/0000-0001-8284-8547)
- Yurong Li (ORCID: https://orcid.org/0000-0001-5819-7895)
- Jinling Yuan
- Lei Qiu (ORCID: https://orcid.org/0000-0003-2956-2528)
- Ding Zhou (ORCID: https://orcid.org/0000-0001-6395-5873)
- Xin Guan (ORCID: https://orcid.org/0000-0001-7629-0591)
Institutions
- China Pharmaceutical University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Nanjing Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tcr-2025-415
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00